Objective: To investigate the effect of raloxifene therapy on menopausal symptoms, depression and anxiety scores using Kupperman's Scale, Hamilton Depression Rating Scale (HDRS) and Beck Anxiety Rating Scale (BARS) in osteopenic postmenopausal women.
Methods: This was a prospective, randomised, parallel and open labeled clinical study. One-hundred thirty-two postmenopausal osteopenic women with natural menopause enrolled into the study. One-hundred twenty-four of them completed the study. Group I patients were treated with oral raloxifene (60 mg/day), Group II patients were treated with oral calcium supplementation (1000 mg/day) for 3 months. The patient's menopausal, depressive and anxiety symptoms were assessed by using Kupperman's Scale, HDRS and BARS, before and at the end of treatment. For statistical analysis unpaired t, ANOVA, RM-ANOVA, MANCOVA, Pearson correlation tests were used. Statistical significance level was established at p < 0.05.
Results: Baseline Kupperman's Scale, HDRS and BARS scores were not different among two groups. At the end of 3 months of therapy, there was improvement in menopausal symptoms, depression and anxiety scores within both groups. When we compared change of scores before and after the treatment; group I scores were better than group II scores.
Conclusion: Our results suggest that raloxifene may have a positive effect on mood in osteopenic postmenopausal women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/0167482X.2010.524718 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eldecalcitol Add-On to Risedronate Reduces Bone Loss from Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
J Clin Endocrinol Metab
January 2025
Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Context: Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR+EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.
View Article and Find Full Text PDFThe DLEU2-miR-15a-16-1 Cluster Is a Determinant of Bone Microarchitecture and Strength in Postmenopausal Women and Mice.
Int J Mol Sci
November 2024
Blood Sciences (Pathology), James Cook University Hospital, Middlesbrough TS4 3BW, UK.
This study explores how select microRNAs (miRNAs) influence bone structure in humans and in transgenic mice. In trabecular bone biopsies from 84 postmenopausal women (healthy, osteopenic, and osteoporotic), we demonstrate that (deleted in lymphocytic leukemia 2)-encoded is strongly positively associated with bone mineral density (BMD) at different skeletal sites. In bone transcriptome analyses, levels correlated positively with the osteocyte characteristic transcripts (encoding sclerostin) and (Matrix Extracellular Phosphoglycoprotein), while the related showed a negative association with BMD and osteoblast markers.
View Article and Find Full Text PDFComparison of the Effect of Selective Serotonin and Norepinephrine Reuptake Inhibitors on Bone Mineral Density with Selective Serotonin Reuptake Inhibitors and Healthy Controls.
J Clin Densitom
October 2024
Madalyon Psychiatry Clinic, Levent, İstanbul, Turkey.
Article Synopsis
- * Sixty-three patients on SNRIs (venlafaxine, duloxetine) and sixty patients on SSRIs underwent assessments, showing that SSRI users had lower bone density values compared to SNRI users, who demonstrated normal bone density.
- * The findings suggest that SNRIs, particularly duloxetine, may pose a lower risk for osteoporosis compared to SSRIs, indicating the need for more research to confirm these results.
Effects of Cannabidiol on Bone Quality in Ovariectomized Rats.
Calcif Tissue Int
November 2024
Ribeirao Preto Medical School, University of Sao Paulo, Rua Pedreira de Freitas, s/n, Ribeirao Preto, Sao Paulo, 14090092, Brazil.
The incidence of osteoporosis and related fractures increases significantly with age, impacting public health and associated costs. Postmenopausal osteoporosis results from increased bone resorption due to decreased estrogen levels. The endocannabinoid system, especially cannabidiol (CBD), has shown therapeutic potential in modulating bone formation.
View Article and Find Full Text PDFOsteogenic effect of an adiponectin-derived short peptide that rebalances bone remodeling: a potential disease-modifying approach for postmenopausal osteoporosis therapy.
Arch Pharm Res
September 2024
Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
Article Synopsis
- Adiponectin is a protein that helps control how our bodies use sugar and fat, and there's a special piece of it called ADP-1 that can help build bones better than the whole protein.
- Researchers found that ADP-1 helps bone cells called osteoblasts grow and work by using two different methods, one involving energy production and the other involving a signaling pathway important for bone health.
- In tests on rats with weak bones, ADP-1 improved bone strength and structure by encouraging new bone formation and stopping the breakdown of old bone, which could help people with osteoporosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!